Skip to main content

    3 firms maintain Candel Therapeutics (CADL) ratings following its earnings report

    GNG Research Market News

    By GNG Research

    Three firms reiterated ratings on Candel Therapeutics Inc (CADL) on November 13, 2026. Three bullish, zero neutral, zero bearish. No firm changed its rating.

    FirmRatingTier
    Canaccord GenuityBuybullish
    HC Wainwright & Co.Buybullish
    StifelBuybullish

    The past 90 days include five active firms, with five rating the stock bullish. 10 analysts set consensus price targets as of November 10, 2026, with a mean of $23.33, a median of $24.48 and a range of $15.15 to $30.45.

    Consensus Q4 FY2026 EPS is -$0.38, with revenue at $0. The next earnings report is on March 10, 2027.